Washington, D.C. - In a recent 10-week, three-dose phase II trial of inflaximab (Remicade), 87.9 percent of the 250 participants achieved PASI 75, while 58 percent achieved PASI 90 at the 10-week mark.
Dermal Infusions and Injections Lead to Improved Skin Quality
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
The Weekly Roundup: March 27-31
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
What's Trending in Skin Care: March 2023
Treating Dermatological Conditions by Going Beyond the Skin
2 Clarke Drive Cranbury, NJ 08512